DRL gears up for biosimilar push, consumer health growth post record FY25
Dr Reddy’s stock rose 5.5% in six sessions post-Q4 results, outperforming the BSE Healthcare index. Strong revenue growth, biosimilar launches, and semaglutide portfolio support long-term prospects despite Revlimid taper and reduced target prices by (...)
Site référencé: The Economic Times
The Economic Times
'Republic of Balochistan announced' trends on social media as Baloch leaders declare independence from Pakistan
14/05/2025
Tesla to resume shipping Chinese parts for Cybercab, Semi production in the US, source says
14/05/2025
Gold Price Today : Gold prices witness profit booking, trade lower by Rs 450/10g, silver down by Rs 700/kg
14/05/2025
Brazil's Lula says to push Putin to negotiate with Zelensky in Istanbul
14/05/2025
GRSE shares zoom 14% after Q4 PAT jumps over 2x YoY
14/05/2025
Breakout Stocks : How to trade Redington, BSE and APL Apollo after fresh 52-week highs
14/05/2025
